Cipla Launches Yurpeak for Obesity, Type 2 Diabetes

• Cipla launched Yurpeak, a once-weekly injectable therapy for obesity and Type 2 diabetes in India.
• Yurpeak is Lilly's tirzepatide, a dual agonist of GIP and GLP-1 receptors, distributed by Cipla after DCGI approval.
• It's indicated for adults with obesity (BMI >= 30) or overweight (BMI >= 27) with weight-related comorbidity, and for Type 2 diabetes.
• Available in KwikPen format across six strengths (2.5 mg to 15 mg), enabling precise and convenient dosing.
• Cipla aims to expand access nationwide, leveraging its distribution network, and will provide patient education and support programs.

Why It Matters: New drug Yurpeak expands access to vital obesity and diabetes treatment in India.